PYXS vs. ENGN, KRRO, GLUE, CTNM, RVNC, RGNX, TSHA, CRVS, ALMS, and PGEN
Should you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include enGene (ENGN), Korro Bio (KRRO), Monte Rosa Therapeutics (GLUE), Contineum Therapeutics (CTNM), Revance Therapeutics (RVNC), REGENXBIO (RGNX), Taysha Gene Therapies (TSHA), Corvus Pharmaceuticals (CRVS), Alumis (ALMS), and Precigen (PGEN). These companies are all part of the "pharmaceutical products" industry.
Pyxis Oncology vs.
enGene (NASDAQ:ENGN) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk, analyst recommendations and community ranking.
enGene presently has a consensus price target of $29.78, indicating a potential upside of 317.06%. Pyxis Oncology has a consensus price target of $9.43, indicating a potential upside of 528.57%. Given Pyxis Oncology's higher possible upside, analysts plainly believe Pyxis Oncology is more favorable than enGene.
Pyxis Oncology received 12 more outperform votes than enGene when rated by MarketBeat users. However, 100.00% of users gave enGene an outperform vote while only 82.35% of users gave Pyxis Oncology an outperform vote.
enGene's return on equity of -16.69% beat Pyxis Oncology's return on equity.
In the previous week, enGene had 6 more articles in the media than Pyxis Oncology. MarketBeat recorded 6 mentions for enGene and 0 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.00 beat enGene's score of -0.41 indicating that Pyxis Oncology is being referred to more favorably in the news media.
enGene has a beta of -0.65, indicating that its share price is 165% less volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.
enGene is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
64.2% of enGene shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 13.7% of enGene shares are owned by company insiders. Comparatively, 9.8% of Pyxis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
enGene beats Pyxis Oncology on 11 of the 16 factors compared between the two stocks.
Get Pyxis Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pyxis Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:PYXS) was last updated on 1/21/2025 by MarketBeat.com Staff
Free PYXS Stock Alerts